Navigation Links
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain

SAN FRANCISCO, July 16, 2014 /PRNewswire/ -- Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. With ADYX-003, Adynxx will build on the results of the recently completed ADYX-002 Phase 2 proof-of-concept study.

The 120-patient, placebo-controlled study will evaluate the safety and efficacy of two dose-volume levels of a single administration of AYX1 given prior to unilateral total knee replacement to reduce acute pain with movement and to prevent the transition to persistent pain. The study will follow patients for 42 days with a primary endpoint of pain with walking. Secondary endpoints include pain at rest, pain with knee range of motion, opioid consumption and extent of functional recovery. Further details of the study can be found at

"In the ADYX-002 proof-of-concept study, AYX1 was well-tolerated and demonstrated a consistent treatment effect across a spectrum of pre-defined movement-evoked pain and range-of-motion assessments. Further, this first efficacy study was very informative regarding the dose-volume relationship that drives the AYX1 treatment effect at its site of action," said Donald Manning, M.D., Ph.D., chief medical officer of Adynxx. "The current ADYX-003 study is designed to leverage these first Phase 2 data to further enhance the scope and magnitude of the AYX1 therapeutic effect." 

"The clinical results to date support Adynxx's approach to the treatment of pain and we are committed to advancing the development of AYX1 as rapidly as possible," added Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx. "Given the lack of effective treatment options for movement-evoked pain after surgery, we believe AYX1 has the potential to transform the therapeutic paradigm by preventing pain for the millions of patients who undergo surgery every year."

About Adynxx

Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery. Funded by Domain Associates, Adynxx has successfully completed a safety Phase 1 and a proof-of-concept phase 2 clinical study of AYX1.  Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.

For more information please visit

Corporate Contact
William Martin
Director, Operations
(415) 512-7740

Media Contacts
David Schull
Matt Middleman, M.D.
(212) 845-4271
(212) 845-4272

Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
2. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
3. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
4. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
5. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
6. MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
7. Tandem Diabetes Care Initiates Voluntary Recall for Specific Lots of Insulin Cartridges Used with t:slim Insulin Pump
8. Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
9. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
10. Cameron Associates Initiates Coverage of Brainsway, Ltd.
11. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
Post Your Comments:
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... Ltd. (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical ... the simultaneous treatment of various clinical conditions, today announced ... of 3,158,900 American Depository Shares ( ADSs ), each ... to purchase up to 3,158,900 ADSs. The ADSs and ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will be ... Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% ... IguanaMed at a discounted price. , IguanaMed’s mission is to outfit every ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse ... the findings on the website. Click here to read the details now. ... who were treated with chemotherapy followed by EPP surgery. Among the 106 patients who ...
Breaking Medicine News(10 mins):